

DISCLAIMER

This Molina Clinical Policy (MCP) is intended to facilitate the Utilization Management process. Policies are not a supplementation or recommendation for treatment; Providers are solely responsible for the diagnosis, treatment and clinical recommendations for the Member. It expresses Molina's determination as to whether certain services or supplies are medically necessary, experimental, investigational, or cosmetic for purposes of determining appropriateness of payment. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (e.g., will be paid for by Molina) for a particular Member. The Member's benefit plan determines coverage – each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their Providers will need to consult the Member's benefit plan to determine if there are any exclusion(s) or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and a Member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a State, the Federal government or CMS for Medicare and Medicaid Members. CMS's Coverage Database can be found on the CMS website. The coverage directive(s) and criteria from an existing National Coverage Determination (NCD) or Local Coverage Determination (LCD) will supersede the contents of this MCP and provide the directive for all Medicare members. References included were accurate at the time of policy approval and publication.

OVERVIEW

Myelodysplastic syndromes (MDS) consist of a heterogeneous group of malignant hematopoietic stem cell disorders characterized by dysplastic and ineffective blood cell production and a varying risk of transformation to acute leukemia. Patients with MDS have reductions in the production of red blood cells, platelets, and mature granulocytes – abnormalities often result in anemia, bleeding, and increased risk of infection. MDS occur predominantly in older patients (≥ 60 years). The median age at diagnosis is approximately 70 years however, patients as young as 2 years have been reported. Older men are more commonly affected by MDS, but the isolated chromosome 5q deletion subtype (del5q) is more common in women. Signs and symptoms at presentation of MDS are nonspecific. Many patients are asymptomatic at diagnosis and only come to the provider's attention based upon abnormalities found on routine blood counts (e.g., anemia, neutropenia, and thrombocytopenia). Others present with symptoms or complications resulting from a previously unrecognized cytopenia (e.g., infection, fatigue). The diagnosis of MDS is made based upon an evaluation of the bone marrow and peripheral smear. The revised International Prognostic Scoring System (IPSS-R) should be used to incorporate information on bone marrow blast percentage, karyotype, and cytopenias for the purpose of stratifying the MDS into risk groups to guide management. Patients with a very low (≤ 1.5 points) or low (>1.5 to 3 points) IPSS-R score are primarily treated with supportive care or low intensity therapies such as azacitidine or decitabine or immunosuppressive therapy. Patients with a high (>4.5 to 6 points) or very high (>6 points) IPSS-R score with a good performance status are primarily treated with combination chemotherapy or allogeneic HCT in an attempt to alter the disease course. Treatment options for patients with an intermediate-risk (>3 to 4.5 points) IPSS-R score include those therapies used for patients with low- or very low-risk IPSS-R scores, and the more intensive therapies typically used for patients with high- or very high-risk IPSS-R scores. Allogeneic hematopoietic cell transplantation (HCT) is a treatment option for patients with intermediate, high, or very high-risk MDS. (Chao, 2022; Deeg & Sandmaier, 2022; ¹⁻² Negrin, 2022; Sekeres & Platzbecker, 2022; Aster & Stone, 2021; DynaMed, n.d.; MDS, n.d.).

Stem-cell transplantation refers to transplantation of hematopoietic stem cells (HSCs) from a donor into a patient. HSCs are immature cells that can develop into any of the three types of blood cells (red cells, white cells or platelets). HSCs are created in the bone marrow and are found in the bone marrow and peripheral blood. There is also a high concentration of HSCs in umbilical-cord blood. Hematopoietic stem cell transplantation (HSCT) can be either autologous (using the person's own stem cells) or allogeneic (using stem cells from a donor). In allogeneic HSCT, it is preferable for donors to have a human leukocyte antigen (HLA) type that is identical to the recipient. Matching is performed on the basis of variability at three of more loci of the HLA gene (e.g., HLA-A, HLA-B, HLA-DRB1). As HLA variability increases, transplant-related morbidity and mortality, including graft rejection and graft-versus-host disease, also increase. (Chao, 2022; Deeg & Sandmaier, 2022; ¹⁻² Negrin, 2022; Sekeres & Platzbecker, 2022; Aster & Stone, 2021; DynaMed, n.d.).

The goal of the pretransplant evaluation is to assess the ability of a patient to tolerate the surgery, post-operative immunosuppression, and transplant care. An extensive cardiopulmonary evaluation, screening for occult infection or cancer, and psychosocial evaluation is standard. Specific testing varies depending upon the patient's age, medical history, and transplant center practice. In addition, while a certain battery of tests may initiate the work up, more testing

Molina Clinical Policy
Hematopoietic Stem Cell Transplantation for
Myelodysplastic Syndromes (MDS): Policy No. 309

Last Approval: 10/12/2022

Next Review Due By: October 2023



may be indicated depending upon the condition of the patient or the initial test results. In addition to a standard medical evaluation the initial assessment should include a psychological and social support evaluation to identify issues that may impair a successful outcome after transplantation. These include a lack of information about the nature of the transplant procedure and post-transplant care, drug or alcohol dependence, compliance with complex medical and behavior regimens. The assessment includes education of the family and the support network of the patient because compliance with complex medical and behavior treatment is critical after any organ transplant procedure. Recipients must be able to incorporate complicated medications, follow-up appointments, and frequent laboratory visits into their schedules. Having an adequate support network aware of these requirements will encourage patient compliance and long-term success. (Chao, 2022; Deeg & Sandmaier, 2022; ¹⁻² Negrin, 2022; Sekeres & Platzbecker, 2022; Aster & Stone, 2021; DynaMed, n.d.).

COVERAGE POLICY

All transplants require prior authorization from the Corporate Transplant Department. Solid organ transplant requests will be reviewed by the Corporate Senior Medical Director or qualified clinical designee. All other transplants will be reviewed by the Corporate Senior Medical Director or covering Medical Director. If the criteria are met using appropriate NCD and/or LCD guidelines, State regulations, and/or MCP policies the Corporate Senior Medical Director's designee can approve the requested transplant.

Office visits with participating Providers do NOT require prior authorization. Providers should see the Member in office visits as soon as possible and without delay. Failure to see the Member in office visits may be considered a serious quality of care concern.

Pre-Transplant Evaluation

(NCCN, 2022; Kanate et al., 2020; AMR, 2018; Della Porta et al., 2017; CMS, 2016; Majhail et al., 2015; MDS, n.d.; ¹⁻⁵ NMDP, n.d.)

Please see MCP-323 Pre-Transplant Evaluation for additional criteria and information.

Criteria for transplant evaluation include:

1. History and physical examination; **AND**
2. Psychosocial evaluation and clearance:
 - a. No behavioral health disorder by history or psychosocial issues:
 - If history of behavioral health disorder, no severe psychosis or personality disorder;
 - Mood/anxiety disorder must be excluded or treated;
 - Member has understanding of surgical risk and post procedure compliance and follow-up required.

AND

- b. Adequate family and social support.

AND

3. EKG; **AND**
4. Chest x-ray; **AND**
5. Cardiac clearance in the presence of any of the following:
 - a. Chronic smokers; **OR**
 - b. Members > 50 years age; **OR**
 - c. Those with a clinical or family history of heart disease or diabetes.

AND

6. Pulmonary clearance if evidence of pulmonary artery hypertension (PAH) or chronic pulmonary disease; **AND**

Molina Clinical Policy
Hematopoietic Stem Cell Transplantation for
Myelodysplastic Syndromes (MDS): Policy No. 309

Last Approval: 10/12/2022

Next Review Due By: October 2023



7. Neurological exam and clearance for transplant including **ONE** of the following:
- Normal exam by H&P; **OR**
 - Abnormal neurological exam with positive findings including **ONE** of the following:
 - Lumbar puncture normal cytology; **OR**
 - Lumbar puncture with cytological exam abnormal: CNS disease treated prior to clearance.

AND

8. A Performance Status that includes **ONE** of the following:
- Karnofsky score 70-100%; **OR**
 - Eastern Cooperative Oncology Group (ECOG) Grade 0-2.

AND

9. Lab studies that include:
- Complete blood count; kidney profile (blood urea nitrogen, creatinine); electrolytes; calcium; phosphorous; albumin; liver function tests; and coagulation profile (prothrombin time, and partial thromboplastin time);*
 - Serologic screening for: HIV; Epstein Barr virus (EBV); Hepatitis virus B (HBV); Hepatitis C (HCV); cytomegalovirus (CMV); RPR and/or FTA:*
 - If HIV positive **ALL** of the following must be met:
 - CD4 count >200 cells/mm-3 for >6 months; **AND**
 - HIV-1 RNA undetectable; **AND**
 - On stable anti-retroviral therapy >3 months; **AND**
 - No other complications from AIDS (e.g., opportunistic infection, including aspergillus, tuberculosis, coccidioides mycosis, resistant fungal infections, Kaposi's sarcoma, or other neoplasm).
 - If abnormal serology, need physician plan to address and/or treatment as indicated.
 - Antinuclear antibody, smooth muscle antibody, antimitochondrial antibody
 - Ceruloplasmin, α 1-antitrypsin phenotype
 - Alpha-fetoprotein - Urine drug screen (UDS) if Member is current or gives a history of past drug abuse.

AND

10. Colonoscopy (if indicated or if Member is age \geq 50) with complete workup and treatment of abnormal results as indicated; an initial screening colonoscopy after initial negative screening requires a follow-up colonoscopy every 10 years).*

AND

11. Gynecological examination with Pap smear for women ages \geq 21 to \leq 65 years of age or if indicated (not indicated in women who have had a total abdominal hysterectomy [TAH] or a total vaginal hysterectomy [TVH]) within the last three years with complete workup and treatment of abnormal results as indicated.

Within the last 12 months:

- Dental examination or oral exam showing good dentition and oral care or no abnormality on panorex or plan for treatment of problems pre- or post-transplant; **AND**
- Mammogram (if indicated or > age 40) with complete workup and treatment of abnormal results as indicated;* **AND**
- PSA if history of prostate cancer or previously elevated PSA with complete workup and treatment of abnormal results as indicated.*

* Participating Centers of Excellence may waive these criteria.

Molina Clinical Policy
Hematopoietic Stem Cell Transplantation for
Myelodysplastic Syndromes (MDS): Policy No. 309

Last Approval: 10/12/2022

Next Review Due By: October 2023



Criteria for Hematopoietic Allogeneic Stem Cell Transplantation (HSCT)

(NCCN, 2022; Kanate et al., 2020; AMR, 2018; Della Porta et al., 2017; CMS, 2016; Majhail et al., 2015; MDS, n.d.; ¹⁻⁵ NMDP, n.d.)

Hematopoietic Allogeneic Stem Cell Transplantation (HSCT) ablative or non-myeloablative from a human leukocyte antigen (HLA)-matched donor (e.g., at least six out of eight match of the HLA-A, HLA-B, HLA-C and HLA-DRB1 markers) or from cord blood when there are no matched sibling or unrelated donors (e.g., at least four out of six match of the HLA-A, HLA-B and HLA-DRB-1 markers) **may be authorized in adults and children** for the treatment of Myelodysplastic Syndromes (MDS) when **ANY** of the following criteria are met:

1. All pre-transplant criteria are met; **AND**
2. Member has **ANY** of the following clinical indications:
 - a. Any intermediate or high IPSS or IPSS-R score* defined as having an IPSS-R score of >3-4.5 (intermediate) or >4.5 (high/very high); **OR**
 - b. Any MDS with poor prognostic features including any of the following:
 - Treatment related MDS; **OR**
 - Refractory cytopenias; **OR**
 - Adverse cytogenetics and molecular features; **OR**
 - Transfusion dependence; **OR**
 - Failure of hypomethylating agents or chemotherapy; **OR**
 - Moderate to severe marrow fibrosis,

*NOTE: Risk stratification is according to the International Prognostic Scoring System (IPSS). This score is available from [MDS](#).

AND

3. The requesting transplant recipient should not have any of the following absolute contraindications:
 - a. Cardiac, pulmonary, and nervous system disease that cannot be corrected and is a prohibitive risk for surgery; **OR**
 - b. Malignant neoplasm with a high risk for reoccurrence, non-curable malignancy (excluding localized skin cancer); **OR**
 - c. Systemic and/or uncontrolled infection; **OR**
 - d. AIDS (CD4 count < 200cells/mm³); **OR**
 - e. Unwilling or unable to follow post-transplant regimen:
 - Documented history of non-compliance
 - Inability to follow through with medication adherence or office follow-up

OR

- f. Chronic illness with one year or less life expectancy; **OR**
- g. Limited, irreversible rehabilitation potential; **OR**
- h. Active untreated substance abuse issues, requires documentation supporting free from addiction for minimally 6 months if previous addiction was present; **OR**
- i. No adequate social/family support.

AND

4. The requesting transplant recipient should be evaluated carefully and potentially treated if any of the relative contraindications below are present. (Irreversible lung disease patients require consultation and clearance by a Pulmonologist prior to consideration of transplantation).
 - a. Smoking, documentation supporting free from smoking for 6 months; **OR**
 - b. Active peptic ulcer disease; **OR**
 - c. Active gastroesophageal reflux disease; **OR**
 - d. CVA with long term impairment that is not amendable to rehabilitation or a patient with CVA/transient ischemic attack within past 6 months; **OR**
 - e. Obesity with body mass index of >30 kg/m² may increase surgical risk; **OR**
 - f. Chronic liver disease such as Hepatitis B/C/D, or cirrhosis which increases the risk of death from sepsis and hepatic failure requires consultation by a gastroenterologist or hepatologist; **OR**
 - g. Gall bladder disease requires ultrasound of the gall bladder with treatment prior to transplantation.

Molina Clinical Policy
Hematopoietic Stem Cell Transplantation for
Myelodysplastic Syndromes (MDS): Policy No. 309

Last Approval: 10/12/2022

Next Review Due By: October 2023



Criteria for Subsequent Hematopoietic Allogeneic Stem Cell Transplantation (HSCT)

Hematopoietic Allogeneic Stem Cell Transplantation (HSCT) (ablative or non-myeloablative) **may be authorized after the first prior stem cell transplantation has occurred only one time** for members with MDS who meet all of the above criteria for transplant and have **ANY** of the following:

1. Primary graft failure indicated by no signs of engraftment* by 42 days after the transplant; **OR**
2. Failure to engraft*; **AND**
3. Late relapse (greater than 18 months after HCT) as salvage therapy.

*NOTE: Engraftment is defined as the first 3 consecutive days on which the absolute neutrophil count (ANC) exceeds $5 \times 10^9/L$ or $> ANC500$ at any time after transplantation (⁴⁻⁵ NMDP, n.d.).

For Members with Significant or Daily Marijuana Use

1. Documentation of compliance with a physician prescribed and managed program of abstinence, and a reasonable expectation that the Member will be abstinent from marijuana use during the transplant and immediate post-transplant time period. Daily marijuana use is an absolute contraindication for both transplant and pre-transplant evaluation unless there is a state mandate applicable for medical marijuana use and transplants, and there is documentation of Member compliance with a physician prescribed plan of care for prescribed marijuana use.
2. If the Member's marijuana use is in compliance with a formal, State-based program for managed medical marijuana, the request should include:
 - Documentation of the Plan of Care for medical marijuana (including the medical decision making that supports the use of medical marijuana); **AND**
 - Transplant Provider agreement with the Plan of Care (including agreement to be accountable for managing the Member's use of medical marijuana).

Continuation of Therapy

When extension of a previously approved transplant authorization is requested, review using updated clinical information is appropriate.

1. If Molina Healthcare has authorized prior requests for transplantation **ALL** of the following information is required for medical review:
 - a. Presence of no absolute contraindication as listed above; **AND**
 - b. History and physical within the last 12 months; **AND**
 - c. Kidney profile within the last 12 months; **AND**
 - d. Cardiac update if history of cardiac disease within two years (≥ 50 years of age); **AND**
 - e. Psychosocial evaluation or update within the last 12 months; **AND**
 - f. Per initial and updated history and physical, any other clinically indicated tests and/or scans as determined by transplant center physician or Molina Medical Director.
2. If authorized prior requests for transplantation were obtained from another insurer, **ALL** of the following information is required for medical review:
 - a. Authorization letter/documentation from previous insurer; **AND**
 - b. Presence of no absolute contraindication as listed above; **AND**
 - c. History and physical within the last 12 months; **AND**
 - d. Cardiac update if history of cardiac disease within two years (≥ 50 years of age); **AND**
 - e. Psychosocial evaluation or update within the last 12 months; **AND**
 - f. Per initial and updated history and physical, any other clinically indicated tests and/or scans as determined by transplant center physician or Molina Medical Director.

Molina Clinical Policy

Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes (MDS): Policy No. 309

Last Approval: 10/12/2022

Next Review Due By: October 2023



Limitations and Exclusions

(NCCN, 2022; Kanate et al., 2020; AMR, 2018; Della Porta et al., 2017; CMS, 2016; Majhail et al., 2015; MDS, n.d.; ¹⁻⁵ NMDP, n.d.)

1. A second or repeat autologous or allogeneic (ablative or non-myeloablative) transplant due to persistent, progressive or early relapsed disease.
2. Autologous stem cell transplantation.
3. Hematopoietic stem cell collection, storage and freezing for a future unplanned transplant is not covered.

DOCUMENTATION REQUIREMENTS. Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes. Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive.

SUMMARY OF MEDICAL EVIDENCE

There have been no prospective trials evaluating the timing of allogeneic HCT in patients with MDS. Observational studies and clinical decision analyses suggest that patients with intermediate, high, or very high risk IPSS-R scores and those with intermediate-2 or high risk IPSS scores are most likely to benefit from allogeneic HCT; patients with lower scores are better served by delaying transplantation until progression to higher risk disease, but before transformation to acute myeloid leukemia (Della Porta et al., 2017). The risk of treatment related mortality (TRM) following transplantation varies according to both transplant-related factors (preparative regimen, donor source, HLA-disparity) and patient-related factors (age, comorbidities). TRM is expected to be highest for older patients with comorbidities who undergo a myeloablative transplant from a partially matched unrelated donor as described by Sierra, et al. 387 patients with MDS who underwent myeloablative HLA-matched sibling HCT, TRM at one and three years were 32 and 37 percent, respectively and increased with age. When compared with younger patients, TRM was increased in patients 18 to 30 years (relative risk [RR] 2.9), 31 to 45 years (RR 4.1), and older than 45 years (RR 4.4). (Sierra et al., 2022).

Saber et al. (2013) performed analysis of post-HCT outcomes for MDS. Outcomes of 701 adult MDS patients who underwent HCT between 2002 and 2006 were analyzed: (MRD [n = 176], 8 of 8 HLA-A, -B, -C, -DRB1 allele matched MUD [n = 413], 7 of 8 MUD [n = 112]). Median age was 53 years (range of 22 to 78 years). In multi-variate analyses, MRD HCT recipients had similar DFS and survival rates compared with 8 of 8 MUD HCT recipients (relative risk [RR] 1.13 respectively), and both MRD and 8 of 8 MUD had superior DFS (RR 1.47 respectively) and survival (RR 1.62 and 1.30 respectively) compared with 7 of 8 MUD HCT recipients. The authors concluded that in patients with MDS, MRD remains the best stem cell source followed by 8 of 8 MUD; transplantation from 7 of 8 MUD is associated with significantly poorer outcomes.

Komrokji et al. (2016) indicated that the higher risk MDS patients, defined by the IPSS as intermediate-2 or high-risk groups, consist of 1/3 of MDS patients who have an expected survival of less than 1.5 years. The ability to better define higher risk MDS improved with the proposal of new clinical risk models such as the revised IPSS and by integration of molecular data, including somatic gene mutations; AHSCT remains the only curative option. In higher risk MDS patients, proceeding early with AHSCT is associated with maximum survival gain. The decision to pursue AHSCT is individualized according to disease risk, co-morbidities, and functional status. The role of therapy before AHSCT remains controversial, and the role of post-AHSCT maintenance is evolving. Hypomethylating agents are the only medications that change the natural history of the disease. Azacitidine is the only drug reported to improve OS in higher risk MDS patients. Appropriate use and assessment of response is key for assuring patients benefit of such limited options. Treatment after failure of hypomethylating agents is an unmet need. The role of detectable somatic gene mutations in prognosis and tailoring therapy continue to emerge.

In summary, the published, peer-reviewed scientific literature supports the safety and effectiveness of allogeneic HSCT for the treatment of MDS in selected individuals. However, improved outcomes have not been demonstrated for autologous HSCT compared with conventional chemotherapy in individuals with MDS therefore the role of autologous HSCT for this indication has not been established.

Molina Clinical Policy
Hematopoietic Stem Cell Transplantation for
Myelodysplastic Syndromes (MDS): Policy No. 309

Last Approval: 10/12/2022

Next Review Due By: October 2023



National and Specialty Organizations

The **American Society for Transplantation and Cellular Therapy (ASTCT)** (formerly the American Society for Blood and Marrow Transplantation) published a 2015 clinical guideline on *Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation*. The guideline focused on the role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of MDS stated that a HLA-matched allogeneic donor (sibling, other family member, unrelated individual, or cord blood) SCT is recommended if an appropriate donor is available and that there are insufficient data demonstrating a long term curative outcome for related and unrelated allogeneic SCT. (Majhail et al., 2015).

In 2020, the ASTCT published an update to align with state of the art and emerging indications and therapy as the therapeutic scope of HCT has widened. Also, a new treatment strategy using modified immune effector cells (including chimeric antigen receptor T cells and engineered T-cell receptors) has emerged. Additional highlights of the 2020 guideline update include recommendations for indications for HCT to include new data and to incorporate indications for immune effector cell therapy (IECT), where appropriate. Indications for HCT/IECT were categorized in the following categories (Kanate et al., 2020).

1. Standard of care, where indication is well defined and supported by evidence.
2. Standard of care, clinical evidence available, where large clinical trials and observational studies are not available but have been shown to be effective therapy.
3. Standard of care, rare indication, for rare diseases where demonstrated effectiveness exists but large clinical trials and observational studies are not feasible.
4. Developmental, for diseases where preclinical and/or early-phase clinical studies show HCT/IECT to be a promising treatment option.
5. Not generally recommended, where available evidence does not support the routine use of HCT/IECT; the ASTCT will continue to periodically review and update guidelines as new evidence is available.

The **National Marrow Donor Program (NMDP)** has published the following guidance: *Disease-Specific HCT Indications and Outcomes Data; Engraftment; HLA Matching; Patient Eligibility for HCT; Transplant Consultation Timing; and Treatment Before Transplant*.^(1-6 NMDP, n.d.)

The **National Comprehensive Cancer Network (NCCN)** Guidelines (2022) for Myelodysplastic Syndromes recommend that allogeneic HSCT from an HLA-matched sibling donor or matched unrelated donor is a preferred approach for treating a selected group of patients with MDS, particularly those with high-risk disease. This includes both standard and RIC strategies. In patients who relapse after a prolonged remission following the first transplant, a second transplant or donor lymphocyte infusion immune based therapy may be considered. Whether transplants should be performed before or after patients achieve remission following induction chemotherapy has not been established. Comparative clinical trials are needed to address these issues.

SUPPLEMENTAL INFORMATION

None.

CODING & BILLING INFORMATION

CPT Codes

CPT	Description
	Collection Codes
38205	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic
38206	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous
38230	Bone marrow harvesting for transplantation; allogeneic
38232	Bone marrow harvesting for transplantation; autologous
	Cell Processing Services
38207	Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage

Molina Clinical Policy
Hematopoietic Stem Cell Transplantation for
Myelodysplastic Syndromes (MDS): Policy No. 309



Last Approval: 10/12/2022

Next Review Due By: October 2023

38208	Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor
38209	Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor
38210	Transplant preparation of hematopoietic progenitor cells; specific cell depletion within harvest, T-cell depletion
38211	Transplant preparation of hematopoietic progenitor cells; tumor cell depletion
38212	Transplant preparation of hematopoietic progenitor cells; red blood cell removal
38213	Transplant preparation of hematopoietic progenitor cells; platelet depletion
38214	Transplant preparation of hematopoietic progenitor cells; plasma (volume) depletion
38215	Transplant preparation of hematopoietic progenitor cells; cell concentration in plasma, mononuclear, or buffy coat layer
	Cell infusion codes
38240	Bone marrow or blood-derived peripheral stem cell transplantation; allogeneic
38241	Hematopoietic progenitor cell (HPC); autologous transplantation
38242	Allogeneic lymphocyte infusions
38243	Hematopoietic progenitor cell (HPC); HPC boost

HCPCS Codes

HCPCS	Description
S2140	Cord blood harvesting for transplantation, allogeneic
S2142	Cord blood derived stem-cell transplantation, allogeneic
S2150	Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including pheresis and cell preparation/storage; marrow ablative therapy; drugs; supplies; hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre-and post-transplant care in the global definition

CODING DISCLAIMER. Codes listed in this policy are for reference purposes only and may not be all-inclusive. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement. Listing of a service or device code in this policy does not guarantee coverage. Coverage is determined by the benefit document. Molina adheres to Current Procedural Terminology (CPT®), a registered trademark of the American Medical Association (AMA). All CPT codes and descriptions are copyrighted by the AMA; this information is included for informational purposes only. Providers and facilities are expected to utilize industry standard coding practices for all submissions. When improper billing and coding is not followed, Molina has the right to reject/deny the claim and recover claim payment(s). Due to changing industry practices, Molina reserves the right to revise this policy as needed.

APPROVAL HISTORY

10/12/2022	Policy reviewed, no changes to criteria, included section on marijuana use.
10/13/2021	Policy reviewed, no changes to criteria, added items under National & Specialty Organizations, updated references.
9/18/2019, 9/16/2020	Policy reviewed, no changes to criteria.
3/8/2018	New policy.

REFERENCES

Government Agency

- Centers for Medicare and Medicaid Services (CMS). Medicare coverage database. National coverage determination (NCD) – Stem cell transplantation 110.23. Available from [CMS](https://www.cms.gov/medicare-coverage-database/). Effective Date January 27, 2016. Accessed August 26, 2022.

Evidence Based Reviews and Publications

- AMR Peer Review. Policy reviewed January 8, 2018 by an Advanced Medical Reviews (AMR) practicing, board-certified physician in the areas of Internal Medicine, Oncology, and Hematology.
- Aster JC, Stone RM. Clinical manifestations and diagnosis of the myelodysplastic syndromes. Available from [UpToDate](#). Updated May 6, 2021. Accessed August 26, 2022. Registration and login required.
- Chao NJ. Selection of an umbilical cord blood graft for hematopoietic cell transplantation. Available from [UpToDate](#). Updated April 7, 2022. Accessed August 26, 2022. Registration and login required.
- Deeg HJ, Sandmaier BM. Determining eligibility for allogeneic hematopoietic cell transplantation. Available from [UpToDate](#). Updated February 21, 2022. Accessed August 26, 2022. Registration and login required.
- DynaMed. Myelodysplastic syndrome (MDS) (record no. T114054). Available from [DynaMed](#). Accessed August 15, 2021.

Molina Clinical Policy

Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes (MDS): Policy No. 309

Last Approval: 10/12/2022

Next Review Due By: October 2023



- ¹ Negrin RS. Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation. Available from [UpToDate](#). Updated August 24, 2022. Accessed August 26, 2022. Registration and login required.
- ² Negrin RS. Treatment of intermediate, low, or very low risk myelodysplastic syndromes. Available from [UpToDate](#). Updated July 28, 2020. Accessed August 26, 2022. Registration and login required.
- ³ Sekeres MA, Platzbecker U. Overview of the treatment of myelodysplastic syndromes. Available from [UpToDate](#). Updated June 13, 2022. Accessed August 26, 2022. Registration and login required.

National and Specialty Organizations

- ¹ Kanate AS, Majhail NS, Savani BN, Bredeson C, Champlin RE, Crawford S, et al. Indications for hematopoietic cell transplantation and immune effector cell therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant*. 2020 Jul;26(7):1247-1256. doi: 10.1016/j.bbmt.2020.03.002. Accessed August 26, 2022.
- ² Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DJ, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2015 Nov;21(11):1863-1869. doi: 10.1016/j.bbmt.2015.07.032. Accessed August 17, 2022.
- ³ Myelodysplastic Syndrome Foundation. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes risk assessment calculator. Available from [MDS](#). Accessed August 17, 2022.
- ⁴ National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: Myelodysplastic syndromes (version 3.2022). Available from [NCCN](#). Updated January 13, 2022. Accessed August 17, 2022. Registration and login required (free).
- ⁵ National Marrow Donor Program (NMDP). Disease-specific HCT indications and outcomes data. Available from [NMDP](#).
- ⁶ National Marrow Donor Program (NMDP). Engraftment. Available from [NMDP](#). Accessed August 17, 2022.
- ⁷ National Marrow Donor Program (NMDP). HLA matching. Available from [NMDP](#). Accessed August 15, 2021.
- ⁸ National Marrow Donor Program (NMDP). Patient eligibility for HCT. Available from [NMDP](#). Accessed August 17, 2022.
- ⁹ National Marrow Donor Program (NMDP). Transplant consultation timing. Available from [NMDP](#). Accessed August 17, 2022.
- ¹⁰ National Marrow Donor Program (NMDP). Treatment before transplant. Available from [NMDP](#). Accessed August 17, 2022.

Peer Reviewed Publications

- ¹ Della Porta MG, Jackson CH, Alessandrino EP, Rossi M, Bacigalupo A, van Lint MT, et al. Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. *Leukemia*. 2017 Nov;31(11):2449-2457. doi: 10.1038/leu.2017.88. Accessed August 17, 2022.
- ² Komrokji RS. Current State of the Art: Management of higher risk myelodysplastic syndromes. *Clin Lymphoma Myeloma Leuk*. 2016 Aug;16 Suppl:S39-43. doi: 10.1016/j.clml.2016.02.019. Accessed August 17, 2022.
- ³ Saber W, Cutler CS, Nakamura R, Zhang MJ, Atallah E, Rizzo JD, et al. Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). *Blood*. 2013 Sep 12;122(11):1974-82. doi: 10.1182/blood-2013-04-496778. Accessed August 17, 2022.
- ⁴ Sierra J, Pérez WS, Rozman C, Carreras E, Klein JP, Rizzo JD, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. *Blood* 2002; 100:1997. Available from [PubMed](#). Accessed August 17, 2022.

Other Peer Reviewed and Professional Organization Publications (used in the development of this policy)

- ¹ Eastern Cooperative Oncology Group (ECOG) Performance Status. Available from [ECOG](#). Accessed August 26, 2022.
- ² Garcia-Manero G. Myelodysplastic syndromes: 2015 update on diagnosis, risk-stratification and management. *Am J Hematol*. 2015 Sep;90(9):831-41. doi: 10.1002/ajh.24102. Accessed August 17, 2022.
- ³ Grabska J, Shah B, Reed D, Ali NA, Padron E, Ramadan H, et al. Myelodysplastic syndromes in adolescent young adults: One institution's experience. *Clin Lymphoma Myeloma Leuk*. 2016 Aug;16 Suppl:S53-6. doi: 10.1016/j.clml.2016.02.022. Accessed August 17, 2022.
- ⁴ Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T, et al. Reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. *Biol Blood Marrow Transplant*. 2008 Feb;14(2):246-55. doi: 10.1016/j.bbmt.2007.11.012. Accessed August 17, 2022.
- ⁵ Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. *N Engl J Med*. 2017 Feb 9;376(6):536-547. doi: 10.1056/NEJMoa1611604. Accessed August 17, 2022.
- ⁶ National Cancer Institute (NCI). Myelodysplastic syndromes treatment (PDQ). Available from [NCI](#). Updated June 17, 2021.
- ⁷ Oliansky D, Antin JH, Bennett JM, Deeg HJ, Engelhardt C, Heptinstall KV, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: An evidence-based review. *Biol Blood Marrow Transplant*. 2009 Feb;15(2):137-72. doi: 10.1016/j.bbmt.2008.12.003. Accessed August 17, 2022.
- ⁸ Scott BL, Pasquini MC, Logan B, Wu J, Devine S, Porter DL, et al. Results of a phase III randomized, multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). *Blood and Marrow Transplant Clinical Trials Network (BMT CTN)*. *Blood* (2015) 126 (23): LBA-8. Available [here](#).
- ⁹ Shaffer BC, Ahn KW, Hu ZH, Nishihori T, Malone AK, Valcárcel D, et al. Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. *J Clin Oncol*. 2016 Jun 1;34(16):1864-71. doi: 10.1200/JCO.2015.65.0515. Accessed August 17, 2022.
- ¹⁰ Tamari R, Chung SS, Papadopoulos EB, Jakubowski AA, Hilden P, Devlin SM, et al. CD34-selected hematopoietic stem cell transplants conditioned with myeloablative regimens and antithymocyte globulin for advanced myelodysplastic syndrome: Limited graft-versus-host disease without increased relapse. *Biol Blood Marrow Transplant*. 2015 Dec;21(12):2106-2114. doi: 10.1016/j.bbmt.2015.07.010.

APPENDIX

Reserved for State specific information. Information includes, but is not limited to, State contract language, Medicaid criteria and other mandated criteria.